ג'קאבי 5 מג ישראל - עברית - Ministry of Health

ג'קאבי 5 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

ג'קאבי 15 מג ישראל - עברית - Ministry of Health

ג'קאבי 15 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

ג'קאבי 20 מג ישראל - עברית - Ministry of Health

ג'קאבי 20 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 20 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

ג'קאבי 10 מג ישראל - עברית - Ministry of Health

ג'קאבי 10 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 10 mg - ruxolitinib

סוטנט 12.5 מג ישראל - עברית - Ministry of Health

סוטנט 12.5 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

סוטנט 25 מג ישראל - עברית - Ministry of Health

סוטנט 25 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

סוטנט 50 מג ישראל - עברית - Ministry of Health

סוטנט 50 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 50 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

סיבינקו 100 מג ישראל - עברית - Ministry of Health

סיבינקו 100 מג

pfizer pharmaceuticals israel ltd - abrocitinib - טבליות מצופות פילם - abrocitinib 100 mg - abrocitinib

סיבינקו 200 מג ישראל - עברית - Ministry of Health

סיבינקו 200 מג

pfizer pharmaceuticals israel ltd - abrocitinib - טבליות מצופות פילם - abrocitinib 200 mg - abrocitinib

סיבינקו 50 מג ישראל - עברית - Ministry of Health

סיבינקו 50 מג

pfizer pharmaceuticals israel ltd - abrocitinib - טבליות מצופות פילם - abrocitinib 50 mg - abrocitinib